anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a liquid preparation containing polygluosan, which is characterized by comprising polygluosan, dispersed liquid, flavoring agent, colorant and preservative, wherein the molecular weight of the polygluosan is 600000-1000000, and the content of the polygluosan in unit liquid preparation is 10-20%(g/100ml). The dispersed liquid is selected from distilled water. The flavoring agent is selected from aspartame, sucralose, stevioside, fructose, glucose, syrup, honey, xylitol, mannitol, lactose, sorbitol, maltitol, glycyrrhizin, phyilodulcin and various oral essences for the human body. The colorant can be selected from artificial or synthetic pigment. The preservative is selected from benzoic acid, sodium benzoate and nipagin-type preservatives. The liquid preparation containing polygluosan disclosed by the invention comprises the polygluosan liquid preparation, and can be used for preparing medicines or food with functions of losing weight, regulating the intestinal function and treating constipation or other intestinal diseases.
NEW MATERIAL:The compound of formula [Ar is group of formula II (X1 and X2 are H, nitro, trifluoromethyl, etc.) or formula III; R1 and R2 are H, 1-4C alkyl which may be substituted with lower alkoxy or halogen, etc.; Y is H, 1-18C alkyl which may be substituted with halogen, cyano or allyl, etc.]. EXAMPLE:5-( 1,2-Dimethylethylenedioxyphosphinyl )-2,6-dimethyl-4-(2-chlorophe nyl)-1,4-dihydropyridine-3-carboxylic acid methyl ester. USE:Remedy for cardiovascular diseases. It has activity to suppress the contraction of smooth muscle and cardiac muscle. PREPARATION:For example, the compound of formula Ar-CHO is made to react with the compound of formula IV in a solvent in the presence of a catalytic amount of piperidine under refluxing and the compound of formula V is added to the reaction system and refluxed to obtain the objective compound.
PURPOSE:A skin agent for external use, containing a germanium compound obtained from plants as an active ingredient, capable of giving oxygen to epidermis, dermis and subcutaneous tissue by applying to the skin surface of the human body and improving the nutriment and effective for preventing and treating pigmentation, e.g. liver-spot, etc. CONSTITUTION:A skin agent for external use containing a germanium compound collected or extracted from plants as an active ingredient. Examples of the plants include polypore, ginseng, sweet hydrangea leaf, comfrey, menispermi radix, BANDAI KINOKO (mushroom), fruit of water caltrop, lycii fructus, aloe leaf, etc. The germanium compound is conveniently collected and extracted by a method for digestion with water. The resultant aqueous solution of the plant extract containing the natural germanium compound is filtered and, as necessary, the filtrate is then concentrated to give the skin agent for external use or cosmetic, e.g. liquid formulation or cream, etc. The content of the active ingredient is within 20-5,000ppm, preferably 20-500ppm range. The internal use of a drink containing the natural germanium compound together with the above-mentioned agent for the external use is effective.
A food supplement, either in the form of a snack bar or a beverage, which contains one or more cartilage enhancing supplements is provided. The cartilage supplements include chondroitin, glucosamine, and hyaluronic acid. The food supplement may additionally be fortified with cetyl myristoleate. The beverage is a mixture of a juice drink base which may include a water-based fruit flavored juice prepared using a pasteurization process at a relatively high temperature and a cartilage supplement solution which includes a cartilage supplement prepared at a relatively low temperature. The beverage may be carbonated, non-carbonated or concentrated. The preferred cartilage supplement is glucosamine, preferably associated with a counter ion, more preferably as glucosamine HCl.
The integration of optogenetics in the trigeminal pain circuitry broadens and reinforces existing pain investigations. Similar to research on spinal neuropathic pain, the exploration of the underlying determinants of orofacial pain is expanding. Optogenetics facilitates more direct, specific, and subtle investigations of the neuronal circuits involved in orofacial pain. One of the most significant concerns of both dentistry and medicine is trigeminal neuralgia (TN) management due to its substantial impact on a patient's quality of life. Our objective is to gather insights from preclinical studies conducted in TN employing an optogenetic paradigm, thereby extending the prospects for in-depth neurobiological research. This review highlights optogenetic research in trigeminal pain circuitry involving TN. We outline the central and peripheral regions associated with pain-that have been investigated using optogenetics in the trigeminal pain circuitry. The study further reports its scope and limitations as well as its potential for future applications from bench to bedside.
OBJECTIVE: To assess if dynamic hyperinflation is an independent risk factor for mortality and severe exacerbations in COPD patients.
METHODS: A cohort of 141 patients with stable COPD and moderate to very severe airflow limitation, treated according to conventional guidelines, was followed for a median of 9 years. Clinical characteristics were recorded and arterial blood gases, pulmonary function tests, 6-min walk and incremental exercise test with measurement of respiratory pattern and operative lung volumes were performed. Endpoints were all-cause mortality and hospitalization for COPD exacerbation.
RESULTS: 58 patients died during the follow-up period (1228 patients x year). The mortality rate was higher in patients with dynamic hyperinflation (n = 106) than in those without it (n = 35) (14.6; 95% CI, 14.5-14.8 vs. 7.2; 95% CI, 7.1-7.4 per 1000 patients-year). After adjusting for sex, age, body mass index, pack-years and treatment with inhaled corticosteroids, dynamic hyperinflation was associated with a higher mortality risk (adjusted hazard ratio [aHR], 2.725; 95% CI, 1.010-8.161), and in a multivariate model, comorbidity, peak oxygen uptake and dynamic hyperinflation were retained as independent predictors of mortality. The time until first severe exacerbation was shorter for patients with dynamic hyperinflation (aHR, 3.961; 95% CI, 1.385-11.328), and dynamic hyperinflation, FEV1 and diffusing capacity were retained as independent risk factors for severe exacerbation. Moreover, patients with dynamic hyperinflation had a higher hospitalization risk than those without it (adjusted incidence rate ratio, 1.574; 95% CI, 1.087-2.581).
CONCLUSION: In stable COPD patients, dynamic hyperinflation is an independent prognostic factor for mortality and severe exacerbations.
Embodiments of the invention provide decision support services, including an enhanced user interface. A reason for a clinical visit is determined and an initial workflow may be provided via the user interface during a clinical visit. The workflow may include a set of initial user interface elements that are determined based on a context associated with the clinical visit. The set of initial user interface elements may include a first initial interface element associated with a pre-identified clinical concept. During the clinical visit, a first suggested interface element can be provided. The first suggested interface element is generated during the workflow based on detecting a selection of the first initial interface element. The first suggested interface element can be associated with a first suggested clinical concept that is related to the pre-identified clinical concept.
The instant invention has developed viral vectors encoding a mutant bacterial cytosine deaminase (bCD) gene, which have a higher affinity for cytosine than wild type bCD (bCDwt). The purpose of the present invention was to evaluate cytotoxicity in vitro and therapeutic efficacy in vivo of these vectors in combination with the prodrug 5-FC and ionizing radiation against human glioma. The present study demonstrates that infection with the viral vector expressing the mutant cytosine deaminase gene resulted in increased 5-FC-mediated cell killing, compared with vectors expressing the wild-type gene. Furthermore, a significant increase in cytotoxicity following infection with viral vector expressing the mutant cytosine deaminase gene and radiation treatment of glioma cells in vitro was demonstrated as compared to infection with viral vector expressing the wild-type gene. Animal studies showed significant inhibition of subcutaneous or intracranial tumor growth of D54MG glioma xenografts by the combination of AdbCD-D314A/5-FC with ionizing radiation as compared with either agent alone, and with AdbCDwt/5-FC plus radiation. These data indicate that combined treatment with this mutant enzyme/prodrug therapy and radiotherapy provides a promising approach for cancer therapy.
The experimental group will carry out the sessions of the specific Pain Sciences program. This intervention is based on two educational sessions of 90 and 60 minutes each, separated by one week.
Most meningiomas are benign, slow growing tumors, which rarely progress to a higher grade. The incidence rate of malignant progression is estimated to be 2.98/1000 patient-year. However, non-skull base location is a significant risk factor for progression. The median time to malignant progression is 4.3 years; however, the cumulative rate of progression approaches a plateau after 10 years. Although radiosurgery does not appear to increase the incidence rate(0.5/1000 patient-year), exact comparisons have been difficult because of differences in study populations. The median time to progression is 7.0 years from initial diagnosis and 5.0 years from radiosurgery. The cumulative rate appears to increase even after 10 years. The risk of malignant transformation after radiotherapy may increase in patients with tumor-prone syndromes, with some controversies regarding patients with neurofibromatosis type 2. Although short term follow-up in patients with meningioma suggests that radiosurgery is safe, there is uncertainty regarding its use in pediatric patients, and those with tumor-prone syndromes.
Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
The procaine salt of penicillin (especially penicillin G) is manufactured by bringing together penicillin and procaine in a solvent in which procaine penicillin is relatively insoluble, with the procaine and penicillin in solution in amounts to form substantially more procaine penicillin than will dissolve in the solvent, and with the penicillin present in a purity of at least about 75 per cent, and separating the resulting precipitate.  The process may be effected by reacting in aqueous solution a penicillin salt (e.g. its sodium, potassium or ammonium salt or a water-soluble salt thereof with an organic nitrogenous base such as N-ethylpiperidine) with a procaine salt (e.g. hydrochloride, sulphate, nitrate or formate), or by reacting penicillin (acid) with procaine (base) in an organic solvent or mixture of solvents in which procaine penicillin is relatively insoluble (e.g. an alkyl acetate having 4-9 carbon atoms, such as amyl, isoamyl, butyl or hexyl acetate, or, less suitably, ether or chloroform). Examples are given of both procedures and of medicinal preparations of the product, in one of which phenol is added as a preservative.  The Specification as open to inspection under Sect. 91 comprises also a reference to the calcium salt of penicillin as a starting material.  This subject-matter does not appear in the Specification as accepted.ALSO:An injectable medicinal product comprises finely divided procaine penicillin (especially procaine penicillin G) in suspension in an aqueous medium, or in a vegetable oil (e.g. cottonseed, peanut or sesame oil) or an oily medium containing a small amount of hydrogenated vegetable oil (e.g. partially hydrogenated peanut oil), or in an aqueous emulsion of a vegetable oil (preferably stabilizing with a small amount of a water-soluble and of an oil-soluble emulsifier).  The procaine penicillin and the liquid in which it is to be suspended may (especially when the latter is or contains water) be put up in separate sealed vials and mixed just before use.  Detailed examples are given, in one of which phenol is added as a preservative.
Hao-Fountain syndrome (HAFOUS, OMIM: #616863) is a neurodevelopmental disorder caused by pathogenic variants in the gene USP7 coding for USP7, a protein involved in several crucial cellular homeostatic mechanisms and the recently described MUST complex. The phenotype of HAFOUS is insufficiently understood, yet there is a great need to better understand the spectrum of disease, genotype-phenotype correlations, and disease trajectories. We now present a larger cohort of 32 additional individuals and provide further clinical information about six previously reported individuals. A questionnaire-based study was performed to characterize the phenotype of Hao-Fountain syndrome more clearly, to highlight new traits, and to better distinguish the disease from related neurodevelopmental disorders. In addition to confirming previously described features, we report hyperphagia and increased body weight in a subset of individuals. HAFOUS patients present an increased rate of birth complications, congenital anomalies, and abnormal pain thresholds. Speech impairment emerges as a potential hallmark of Hao-Fountain syndrome. Cognitive testing reports reveal borderline intellectual functioning on average, although some individuals score in the range of intellectual disability. Finally, we created a syndrome-specific severity score. This score neither indicates a sex- nor age-specific difference of clinical severity, yet highlights a more severe outcome when amino acid changes colocalize to the catalytic domain of the USP7 protein.
Thyroid Eye Disease (TED) is an inflammatory autoimmune condition affecting the eyes, often associated with Graves' disease. Inflammation is important in TED, involving immune cells and orbital tissues. While inflammatory markers have been studied in other diseases, their role in TED is unclear. We included 734 participants from 5 eligible studies investigated associations between neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) and TED. Initial analysis found no significant differences in these markers between TED and control groups. However, sensitivity analysis excluding an outlier study revealed significant differences in NLR, PLR, and MLR between groups, suggesting the potential association between these inflammatory markers and TED. More research is needed, but these findings indicate complex TED pathogenesis and that inflammation may offer insights for TED diagnosis and management.
This study is a randomized placebo-controlled trial comparing two antibiotic treatment regimens for acute PID. Women with acute PID will be randomized to one of two treatment regimens. One group of women will receive a single intramuscular dose of ceftriaxone 250 mg, doxycycline 100 mg orally twice a day for 14 days, along with placebo tablets orally twice a day for 14 days. The second group of women will receive the same doses of ceftriaxone and doxycycline, and metronidazole 500 mg orally twice a day for 14 days. The primary objective is to compare the eradication of anaerobic organisms from the upper genital tract in women with acute PID who receive standard outpatient antibiotic treatment to the eradication of these organisms from the upper genital tract in women who receive standard outpatient treatment along with a two-week course of metronidazole. Women will be followed for one month for clinical outcomes, and will undergo assessment for clearance of microorganisms from the upper genital tract. Our hypothesis is that an antibiotic treatment regimen that includes anaerobic coverage will more effectively clear anaerobic organisms from the endometrium in women with acute PID compared to a standard antibiotic treatment regimen lacking effective antibiotic coverage against anaerobes.
Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
BACKGROUND: Lysophosphatidic acid (LPA) is a small bioactive lipid which acts as a potent regulator in various tumor progressions through six G-protein-coupled receptors (LPA1-LPA6). Our previous study demonstrated that the LPA-producing enzyme, autotaxin (ATX), was upregulated in esophageal squamous cell carcinoma (ESCC) and ATX high expression levels indicated a poor prognosis. Esophageal squamous cell carcinoma is a type of malignant tumor which originates from epithelial cells. Its progression can be affected by the interaction between cancer cells and normal cells. However, the impact of LPA on the interaction between esophageal epithelial cells and cancer cells in the development of ESCC remains uncertain.
METHODS: MTS and Edu assays were performed to determine ESCC cell proliferation in culture medium (CM) derived from LPA-stimulated esophageal epithelial cells (Het-1a). A wound healing assay, transwell migration and an invasion assay were performed to assess the metastatic ability of ESCC cells. Cytokine array analysis was conducted to detect the differentially secreted cytokines in CM. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were utilized to uncover the pathways and cytokines that are influenced by LPA in ESCC. Immunohistochemical staining was employed to measure the expression of ATX and CCL2 in early-stage ESCC. Quantitative real-time PCR, western blot, enzyme-linked immunosorbent assay and an antibody neutralization assay were employed to measure the mechanism of LPA-mediated communication between epithelial cells and cancer cells.
RESULTS: Functional experiments showed that exposing ESCC cancer cells to CM from LPA-treated Het-1a results in promoting proliferation, migration, invasion and epithelial-mesenchymal transition processes. Using cytokine array analysis, we discovered that LPA triggers the release of multiple cytokines from epithelial cells. After screening of the TCGA and GEO databases, CCL2 was identified and found to be correlated with ATX expression in ESCC. Furthermore, CCL2 levels in both mRNA expression and secretion were observed to be upregulated in epithelial cells upon stimulation with LPA. Blocking CCL2 effectively reduced the pro-migration influence of CM derived from LPA-treated Het-1a. Mechanism studies have demonstrated that LPA activated the NF-κB signaling pathway through LPA1/3, ultimately causing an increase in CCL2 expression and secretion in Het-1a.
CONCLUSIONS: Our findings, taken together, demonstrate that CM from LPA-treated esophageal epithelial cells plays a significant role in promoting the progression of ESCC, with CCL2 acting as the primary regulator.
BACKGROUND: The prevalence and risk factors of cholelithiasis in individuals with severe or profound intellectual and motor disabilities (SPIMD) are poorly characterised. Thus, we aimed to investigate the prevalence and risk determinants of cholelithiasis in a cohort with SPIMD under medical care in a residential facility.
METHODS: We categorised 84 patients in a residential hospital for persons with SPIMD into groups: those with (Group CL) and without (Group N) cholelithiasis. Gallstones were detected via computed tomography, ultrasonography or both. We evaluated gastrostomy status, nutritional and respiratory support, constipation, and bladder and kidney stones. Data were significantly analysed using univariate and multivariate logistic regression analyses.
RESULTS: The prevalence rate of cholelithiasis in our SPIMD cohort was 27%. There were no significant differences in sex, age, weight, height, or Gross Motor Function Classification System between the two groups. However, more patients received enteral nutrition (39.13% vs. 6.56%; P = 0.000751) and were on ventilator support (56.52% vs. 19.67%; P = 0.00249) in Group CL than in Group N. Enteral nutrition [odds ratio (OR) 10.4, 95% confidence interval (CI) 1.98-54.7] and ventilator support (OR 20.0, 95% CI 1.99-201.0) were identified as independent risk factors for the prevalence of cholelithiasis in patients with SPIMD.
CONCLUSIONS: Patients with SPIMD demonstrated an increased prevalence of cholelithiasis, with a notable association between nutritional tonic use and respiratory support. Therefore, to emphasise the need for proactive screening, it is crucial to devise diagnostic and therapeutic strategies specific to patients with SPIMD. Further investigation is essential to validate our findings and explore causative factors.
The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or \>500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
BACKGROUND: Infection-associated secondary hemophagocytic lymphohistiocytosis (sHLH) is a potentially life-threatening hyperinflammatory condition caused by various infectious diseases. Malaria has rarely been described as trigger. The aim of this study is to collect data on frequency, clinical spectrum, and outcome of sHLH induced by malaria.
METHODS: We collected case numbers on malaria and malaria-associated sHLH from specialized centers in Germany from 2015 to 2022. In addition, we conducted a literature search on published cases of malaria-associated sHLH and systematically analyzed the literature regarding clinical and diagnostic criteria.
RESULTS: We obtained data from 13 centers treating 1461 malaria cases with different Plasmodium species, of which 5 patients (0.34%) also were diagnosed with sHLH. The literature search revealed detailed case reports from further 51 patients and case series comprising the description of further 24 patients with malaria-associated sHLH. Most cases (48/80; 60%) were reported from Asia. The median time interval between onset of malaria symptoms and hospital admission was 7 days. Severe complications of sHLH were documented in 36% (20/56) of patients, including two patients with multiple organ failure in our case series. Only 41% (23/56) of patients received specific treatment for sHLH, nevertheless the mortality rate (CFR) of 5% is lower compared to the CFR reported for sHLH triggered by other infectious diseases (e.g., 25% in sHLH due to EBV infection).
CONCLUSION: Malaria-associated sHLH appears to have a comparatively good prognosis but may still represent an underdiagnosed and potentially fatal complication of malaria, especially in resource-poor settings.
FIELD: medicine. ^ SUBSTANCE: combined vaccines described in the invention contain diphtheria toxoid (D), tetanus toxoid (T), cell pertussis antigen (wP), surface hepatitis type B virus antigen (HBsAg), capsular saccharide Haemophilus influenzae type b (Hib) conjugated with a carrier protein, and capsular saccharide N. meningitidis, mainly serogroups A and C conjugated with a carrier protein; the carrier protein is tetanus toxoid. The weight ratio of saccharide to the carrier makes 1:2 to 1:4. A number of improved versions of said vaccines is disclosed. The vaccines can be compounded immediately before injection by mixing two components: (a) the first component including D, T, Pw and HBsAg antigens, and (b) the second component including Hib-conjugate and one or more meningococcal conjugates which are presented in an appropriate kit for the preparation of vaccine composition. The invention discloses a method for preparing the vaccine by mixing the vaccine components in a certain order and sequence. ^ EFFECT: preparing the improved vaccine combination against six types of infections for protection of patients; also, it shows high tolerability in children. ^ 38 cl, 8 dwg